Hematologist at Jefferson Einstein Philadelphia Hospital specializing in the treatment of Multiple Myeloma Opinions are my own and retweets are not endorsements
Philadelphia, PA
Joined October 2017
- Tweets814
- Following854
- Followers656
- Likes4.7K
Alankrita Taneja, MD retweeted
With Tec-Dara approved today, options for 1st relapse myeloma continue to expand.
Sharing how I currently approach sequencing in clinic, based on emerging data and NCCN discussions. Just one practical framework.
Curious how others are thinking about this. #mmsm #hemetwitter
Alankrita Taneja, MD retweeted
Impact of Duffy genotype on PFS w/ RVd +/- ASCT & continuous R maintenance in Pts w/ NDMM: Updated subgroup analysis of the phase 3 DETERMINATION trial [Nov 3, 2025] @LaurenMerzMD et al. #ASH25 abs25-4186 PID 1033 meetings-api.hematology.org/… #mmsm #bmtsm #CancerDisparities #globonc
Alankrita Taneja, MD retweeted
Daratumumab is now FDA and EU approved for treatment of high risk smoldering myeloma.
It is recommended level 1 by NCCN. My thoughts:
In the AQUILA randomized trial, daratumumab:
-Prolonged time to active myeloma
-Prolonged time to end organ damage
-Delayed time to needing active myeloma therapy
-Improved overall survival
-Improved PFS-2
-Low toxicity
-No detriment to QOL
This is a limited duration (3 years) therapy. This limited duration therapy can prevent or delay full blown typically continuous myeloma therapy by years. Full myeloma therapy is not simple. It involves 4 drug initial therapy, stem cell transplant in eligible patients, and prolonged 1-2 drug maintenance. Delaying time to full myeloma therapy by a long time is in and of itself a big deal.
Watching patients closely and starting therapy only when you see evidence of progression sounds good on paper but in reality will lead to more patients starting full myeloma therapy sooner. It also risks end organ damage between visits. Experts think they can watch carefully but in studies we find progressions are missed at top centers. In real world the type of follow up we did in AQUILA will not be possible. Patients with active myeloma in my experience are struggling to see their doctors in time.
We hope to have more overall survival information soon. But we already see an important improvement.
For more on the trial see nejm.org/doi/full/10.1056/NE…
This will change my practice. Have seen too many side effects with q4 weekly dosing. jamanetwork.com/journals/jam…
Alankrita Taneja, MD retweeted
What is it like to transition from being a #fellow to being an #oncology #attending? Watch as @mhadfield30 and @TanejaMD share their biggest lessons, surprises, and insights from their first year in independent practice!
Watch here! youtu.be/Xn6qONCFvcg
#hemonc #fellowship
This strategy will likely result in increased step-up administration of bispecific antibodies in the community setting ashpublications.org/bloodadv…
Alankrita Taneja, MD retweeted
Excellent - linvo approved for 🇺🇸 pts with myeloma!
👍🏻 Q2W & Q4W built into approval
👎🏻 FDA forced 4 prior lines again
From press release: "0.95 month median time to first response."
When I was a kid, time to 1st response with #MMsm BCMA bsAbs was always exactly 1.2 mo 😉
Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma | Regeneron Pharmaceuticals Inc. #mmsm investor.regeneron.com/news-…
Alankrita Taneja, MD retweeted
Just out! New IMS/ IMWG Definition of High Risk Myeloma.
@JCO_ASCO #IMWG25
@Myeloma_Society @IMFmyeloma @NikhilMunshiMD @mvmateos @SagarLonialMD @szusmani @NoopurRajeMD
My mentee, Chidi, an intern at @TJUHospital Einstein Philadelphia Hospital was awarded the Young Investigator Award at @SocietyofHemOnc for his work on Multiple Myeloma!! So excited for this rising star! 🌟🌟🌟💫
Alankrita Taneja, MD retweeted
'Less is more' maintenance therapy in #MultipleMyeloma!
Triplets→ASCT→3yr Len → D/C if MRD-neg (NGF+PET/CT-neg)
Results: 3yr PFS ~93%, TFS ~75% *Treatment initiated for MRD resurgence
Based on @bdermanmd 's MRD2STOP + this data: I'm comfortable stopping Len in standard-risk MRD-neg patients at 3yrs!
However, with quad induction + MRD-neg 10^-6 by NGS, do we even need 3yrs of Len? As @End_myeloma reminds us, Len maintenance was built on the backbone of doublets!
tinyurl.com/8thww4sz
Had great thought provoking discussions at @LLSusa #myelomarounds #Philadelphia @TJUHospital with Dr Binder and 🌟 fellow Tara
Alankrita Taneja, MD retweeted
#Myeloma Paper of the Day: Study of outcomes in frail pts getting bispecifics finds best ORR 80% in frail vs 73% in non-frail group; no significant difference in median PFS (NR vs 11 mos) or OS (37 vs 25 mos); similar rates of all grade CRS & ICANS: pubmed.ncbi.nlm.nih.gov/4031…. #mmsm
Alankrita Taneja, MD retweeted
Here are my Top 5 #ASH24 @ASH_hematology myeloma abstracts. #ASH24VR
Links to the full abstract. My Top 5 are based on new data, clinical impact, & methodology
Thread with countdown👇
Alankrita Taneja, MD retweeted
#ASH24 24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702. *Omitting 24HRU assessments from IMWG criteria changed <1% of responses and had no impact on PFS prediction at any response depth #mmsm #bmtsm @RahulBanerjeeMD ash.confex.com/ash/2024/webp…
Alankrita Taneja, MD retweeted
#Myeloma Paper of the Day: Cool paper from @RahulBanerjeeMD showing analysis of S0777 and S1211 @SWOG trial data that lowering the dose of dex during induction therapy did not have an impact on long-term outcomes like PFS & OS: pubmed.ncbi.nlm.nih.gov/3932…. #mmsm
Alankrita Taneja, MD retweeted
Alankrita Taneja, MD retweeted
In honor of #InternationalOverdoseAwareness Day, Alankrita Taneja and Matthew Hadfield sat down to discuss, raise #awareness, and #advocate for those who have been affected by an #overdose.
#TogetherWeCan #IOAD2024 #EndOverdose
Listen along here: oncdata.com/international-ov…
Alankrita Taneja, MD retweeted
On #WorldHumanitarianDay, we raise advocate for civilians around the world who are caught up in conflict and honor #humanitarian workers who provide lifesaving support to those in need. #ActForHumanity
Watch as Dr. Taneja and Dr. Hadfield discuss #WHD24! oncdata.com/act-for-humanity…
Alankrita Taneja, MD retweeted
Thrilled to be included in this amazing group of people. The blog I wrote in 2020 still very much resonates with me and what I hear from others. @ASCO #ASCO24 #ascoconnection @n8pennell @DrSGraff @ShikhaJainMD @AshleySumrallMD @NarjustFlorezMD @TanejaMD @GlopesMd – at Chicago, IL
